165 completed, 40 terminated, 26 recruiting, 26 unknown. 293 Phase 2, 41 Phase 1, 33 Phase 3.
Follow Epilepsy: new trials by email Literature Review of Epilepsy trials Research Report on Epilepsy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Electrophysiologic Mechanisms of Ketamine Antidepressant Response Ketamine - Epilepsy, Depressive Symptoms | Phase 2 | Not yet recruiting | Emory University | 37 | 2026-12-01 | 2026-08-17 |
| A Fully Remote Feasibility Trial of Phenylbutyrate for SLC6A1-Related Disorders Glycerol Phenylbutyrate - SLC6A1 | Phase 2 | Recruiting | Scripps Translational Science Institute | 20 | 2026-10-01 | 2026-09-29 |
| A Study to Evaluate the Safety and Efficacy of JZP926 Capsule for the Treatment of Juvenile Myoclonic Epilepsy JZP926 capsule, Placebo - Juvenile Myoclonic Epilepsy | Phase 2 / Phase 3 | Recruiting | Jazz Pharmaceuticals | 260 | 2026-09-18 | 2026-10-06 |
| Safety and Efficacy of AV078 in Participants With Tuberous Sclerosis Complex (TSC) Refractory Epilepsy (RESTOR-1) AV078, Placebo - Tuberous Sclerosis Complex, Epilepsy | Phase 2 | Not yet recruiting | Aeovian Pharmaceuticals, Inc. | 42 | 2026-09-01 | 2026-09-29 |
| Fluorescence Guided Focal Cortical Dysplasia Surgery 5-ALA (Gliolan) - Drug Resistant Epilepsy | Phase 2 | Not yet recruiting | Hospices Civils de Lyon | 5 | 2026-09-01 | 2026-06-18 |
| Efficacy of Probenecid on Cluster Seizures During Anti Seizure Medication Withdrawal in Presurgical Focal Epilepsy Video-EEG Monitoring Probenecid, Placebo - Focal Epilepsy | Phase 2 | Recruiting | Fondation Ophtalmologique Adolphe de Rothschild | 600 | 2026-08-24 | 2026-10-05 |
| CANnabinoids for Drug Resistant Epilepsy (DRE) in Adults and Children Placebo, CBD Isolate, CBD CHE - Drug Resistant Epilepsy | Phase 2 | Not yet recruiting | University of Manitoba | 90 | 2026-07-27 | 2026-06-11 |
| ASCEND: Safety and Tolerability of ION337 for the Treatment of Dravet Syndrome ION337 - Dravet Syndrome | Phase 1 / Phase 2 | Recruiting | Ionis Pharmaceuticals, Inc. | 32 | 2026-05-21 | 2026-09-03 |
| A Long-term Study of the Safety and Effectiveness of RAP-219 in Adults With Focal Onset Seizures RAP-219 - Focal Epilepsy, Epilepsy | Phase 2 | Recruiting | Rapport Therapeutics Inc. | 30 | 2025-12-15 | 2026-01-23 |
| Personalized Antisense Oligonucleotide for A Single Participant (nL62541) With ATN1 Gene Mutation nL-ATN1-001 - Dentatorubral-Pallidoluysian Atrophy | Phase 1 / Phase 2 | Active not recruiting | n-Lorem Foundation | 1 | 2025-11-06 | 2026-04-07 |
| Tianasen (ASO-GNAO1) for GNAO1-Encephalopathy With Epilepsy and Movement Disorders. Antisense oligonucleotide treatment (ASO) - GNAO1, Epilepsy | Phase 1 / Phase 2 | Recruiting | Pirogov Russian National Research Medical University | 5 | 2025-09-09 | 2026-01-23 |
| An Open-label Study to Evaluate Safety, Tolerability, and Efficacy of CB03-154 in Subjects Diagnosed With Epilepsy CB03-154 - Focal Epilepsy | Phase 2 | Recruiting | Shanghai Zhimeng Biopharma, Inc. | 144 | 2025-08-14 | 2025-11-20 |
| SPN-817 Open-Label Extension Study in Adults With Focal Onset Seizures SPN-817 - Focal Onset Seizures | Phase 2 | Enrolling by invitation | Supernus Pharmaceuticals, Inc. | 100 | 2025-07-30 | 2026-10-27 |
| A Study to Prevent Infantile Spasms Relapse Prednisolone, Famotidine, Placebo - Infantile Spasms, Infantile Epileptic Spasms Syndrome | Phase 2 | Recruiting | University of California, Los Angeles | 40 | 2025-05-05 | 2025-05-08 |
| Enhanced MRI Imaging in Healthy Participants and Participants With Epilepsy Ferumoxytol - Epilepsy, Temporal Lobe | Phase 2 | Recruiting | University of Alberta | 50 | 2025-05-01 | 2026-05-08 |
| A Study Evaluating NPT 2042 Versus Placebo in Subjects Aged 16-75 Years With Genetic Generalized Epilepsy (GGE) and Absence Seizures NPT 2042, Placebo - Epilepsy, Generalized, Epilepsy, Absence | Phase 2 | Completed | NeuroPro Therapeutics, Inc. | 14 | 2025-03-11 | 2026-09-28 |
| CBD Delivery with the A-Synaptic GT4 Transdermal Delivery System in with Dravet Syndrome And/or Lennox-Gastaut Syndrome CBD: GT4 Transdermal Delivery System - Lennox-Gastaut Syndrome (LGS), Dravet Syndrome (DS) | Phase 1 / Phase 2 | Not yet recruiting | Alexander Rotenberg | 25 | 2025-01-01 | 2024-12-18 |
| RENAISSANCE 2: SPN-817 Phase 2, Double-Blind, Placebo-Controlled Study in Adults With Focal Onset Seizures SPN-817, Placebo - Focal Onset Seizures | Phase 2 | Recruiting | Supernus Pharmaceuticals, Inc. | 216 | 2024-12-30 | 2026-10-01 |
| BMB-101 in Absence Epilepsy and DEE BMB-101 - Absence Epilepsy, Jeavons Syndrome | Phase 2 | Recruiting | Bright Minds Biosciences Pty Ltd | 20 | 2024-12-05 | 2025-08-12 |
| A Safety and Efficacy of Intrathecally Administered ION283 in Patients With Lafora Disease ION283 - Lafora Disease | Phase 1 / Phase 2 | Recruiting | Berge Minassian | 10 | 2024-12-03 | 2025-12-18 |
Showing 20 of 293. Sign in to see all of them.
Seizures (87) · Epilepsies, Partial (46) · Drug Resistant Epilepsy (38) · Epilepsies, Myoclonic (18) · Spasms, Infantile (16) · Tuberous Sclerosis (10) · Lennox Gastaut Syndrome (9) · Migraine Disorders (9) · Epilepsy, Reflex (8) · Brain Diseases (7) · Epilepsy, Absence (7) · Autistic Disorder (4) · CDKL5 deficiency disorder (4) · Depression (4)
Nervous System Diseases (291) · Central Nervous System Diseases (290) · Brain Diseases (286) · Pathological Conditions, Signs and Symptoms (105) · Signs and Symptoms (102) · Neurologic Manifestations (100) · Epileptic Syndromes (55) · Epilepsy, Generalized (47) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (30) · Genetic Diseases, Inborn (25) · Neurodegenerative Diseases (17) · Congenital Abnormalities (15) · Heredodegenerative Disorders, Nervous System (15) · Neoplasms (14)
Levetiracetam (14) · Cannabidiol (11) · Lacosamide (10) · perampanel (10) · Topiramate (7) · ganaxolone (7) · brivaracetam (6) · Diet, Ketogenic (5) · Everolimus (5) · eslicarbazepine acetate (5) · Cenobamate (4) · Diazepam (4) · Valproic Acid (4) · Clobazam (3) · Ketamine (3)
UCB Pharma (15) · Jazz Pharmaceuticals (10) · Marinus Pharmaceuticals (8) · Eisai Inc. (7) · Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (7) · National Institute of Neurological Disorders and Stroke (NINDS) (6) · SK Life Science, Inc. (6) · Bial - Portela C S.A. (5) · Children's Hospital Medical Center, Cincinnati (5) · Eisai Co., Ltd. (5) · Lady Hardinge Medical College (5) · Neurocrine Biosciences (5) · UCB BIOSCIENCES, Inc. (5) · All India Institute of Medical Sciences (4) · Biohaven Therapeutics Ltd. (4)
United States (173) · Australia (32) · Spain (31) · France (29) · Germany (29) · Poland (26) · United Kingdom (23) · Hungary (21) · Italy (21) · Belgium (20) · Canada (17) · Czechia (15) · India (15) · Netherlands (15) · Mexico (14)
Maciej Gasior, MD, PhD (4) · Ahmed Elkashef, MD (2) · Ann Dandurand, MD (2) · Beverly S Wical, MD (2) · Christopher M DeGiorgio, MD (2) · Dennis J Dlugos, MD (2) · Gary Slatko (2)
PMID 35305920, PMID 37059702, PMID 28086164, PMID 31672143, PMID 31937513, PMID 35285519, PMID 35965432, PMID 41780062, PMID 16450381, PMID 16499758, PMID 16611468, PMID 17888078, PMID 18513353, PMID 18711110, PMID 19001248, PMID 19702752, PMID 20041945, PMID 20547106, PMID 20667792, PMID 21167786, PMID 21332573, PMID 21883097, PMID 21920781, PMID 22771222, PMID 22777131, PMID 22813235, PMID 22913800, PMID 23219031, PMID 23365066, PMID 23533164, PMID 23798472, PMID 23876024, PMID 24999157, PMID 25201887, PMID 25377429, PMID 25461210, PMID 25769377, PMID 25963722, PMID 26696953, PMID 26724782, PMID 26984901, PMID 27265725, PMID 27693237, PMID 28500900, PMID 29373639, PMID 29653338, PMID 29878341, PMID 30146701, PMID 30232735, PMID 30427550
2014 (10), 2018 (6), 2017 (4), 2023 (4), 2015 (3), 2016 (3), 2004 (2), 2019 (2), 2025 (2), R01NS074409 (2), 2005 (1), 2008 (1), K12TR004410 (1), K23AT001933 (1), R01NS042698 (1)